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Severe acute respiratory syndrome coronavirus 
meta-Analysis 
A B S T R A C T   
Introduction: In the current time where we face a COVID-19 pandemic, there is no vaccine or effective treatment 
at this time. Therefore, the prevention of COVID-19 and the rapid diagnosis of infected patients is crucial. 
Method: We searched all relevant literature published up to February 28, 2020. We used Random-effect models to 
analyze the appropriateness of the pooled results. 
Result: Eighty studies were included in the meta-analysis, including 61,742 patients with confirmed COVID-19 
infection. 62.5% (95% CI 54.5–79, p < 0.001) of patients had a history of recent travel endemic area or con-
tact with them. The most common symptoms among COVID-19 infected patients were fever 87% (95% CI 73–93, 
p < 0.001), and cough 68% (95% CI 55.5–74, p < 0.001)), respectively. The laboratory analysis showed that 
thrombocytosis was present in 61% (95% CI 41–78, p < 0.001) CRP was elevated in 79% (95% CI 65–91, p <
0.001), and lymphopenia in 57.5% (95% CI 42–79, p < 0.001). 
The most common radiographic signs were bilateral involvement in 81% (95% CI 62.5–87, p < 0.001), 
consolidation in 73.5% (95% CI 50.5–91, p < 0.001), and ground-glass opacity 73.5% (95% CI 40–90, p < 0.001) 
of patients. Case fatality rate (CFR) in <15 years old was 0.6%, in >50 years old was 39.5%, and in all range 
group was 6%. 
Conclusions: Fever and cough are the most common symptoms of COVID-19 infection in the literature published 
to date. Thombocytosis, lymphopenia, and increased CRP were common lab findings although most patients 
included in the overall analysis did not have laboratory values reported. Among Chinese patients with COVID-19, 
rates of hospitalization, critical condition, and hospitalization were high in this study, but these findings may be 
biased by reporting only confirmed cases.   
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1. Introduction 
In December 2019, the new COVID-19 coronavirus was recognized 
as a cause of respiratory illness. The first reports of pneumonia were 
from people who worked or lived in the Huanan seafood wholesale 
market in Wuhan, China raising concerns about a zoonotic viral infec-
tion [1,2]. Phylogenetic analysis showed that the COVID-19 belong to 
the beta-coronavirus [1]. Epidemiological studies have shown that the 
virus is spread relatively easily and can be transmitted by aerosol, 
droplets, and through infected surfaces [3]. The COVID-19 has now 
spread to more than 50 countries from December 2019 to February 2020 
[4]. Most symptoms are non-specific in patients with respiratory disease. 
According to the latest WHO report, out of 83,652 confirmed cases of 
COVID-19 worldwide, 2791 deaths occurred in China and 67 deaths is 
recorded in other countries [4]. 
Thus far, 6 coronaviruses that are able to infect humans have been 
identified, coronavirus infections are typically asymptomatic or associ-
ated with mild respiratory symptoms [1]. The first coronavirus to cause 
severe disease in humans was the Severe Acute Respiratory Syndrome 
virus (SARS), which was appeared in the Guangdong province of 
southern China in 2002, there were 8098 reported case and 774 deaths 
[5]. In Saudi Arabia in 2012, the Middle East respiratory syndrome 
coronavirus (MERS-CoV), which was transmitted from the camels to 
humans, caused 2458 infections with 848 deaths [6]. 
Clinical studies have shown that COVID-19 can rapidly cause pul-
monary damage and severe respiratory symptoms [3]. There is no 
vaccine or targeted treatment currently available for COVID-19 infec-
tion. Treatment is largely supportive although multiple experimental 
antiviral medications are being evaluated [7,8]. Thus, prevention and 
rapid diagnosis of infected patients is crucial. To date, the published 
clinical studies are quite small and give variable findings. With this in 
mind, here we evaluate the clinical features and laboratory findings 
using a large sample size of COVID-19 infected patients in order to assist 
in its understanding, prevention and treatment. 
2. Methods 
2.1. Search strategy 
This study was conducted according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses statement (PRISMA) guide-
lines [9]. We searched all studies published up to February 28, 2020 
from the following databases: Embase, Scopus, PubMed, Web of Science 
and the Cochrane library. Search medical subject headings (MeSH) 
terms used were: “COVID-19”, “Coronavirus”, “severe acute respiratory 
syndrome coronavirus”, and all their synonyms like “Wuhan Coronavi-
rus”, “SARS-CoV-2”, and “COVID-19”. Moreover, we searched for un-
published and grey literature with Google scholar, Center for Disease 
Controls (CDC) and WHO databases. We also examined references of 
included articles to find additional relevant studies. There was no lan-
guage restriction and all included studies are written in English or 
Chinese languages, the latter were translated by https://translate.goo 
Fig. 1. Flow Diagram of Literature Search and Study Selection (PRISMA flow chart).  
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Table 1 
Characterization of Included Studies with total 61, 742 COVID-19 Confirmed Patients. All Studies are Retrospective, from China, and Published in 2020.  











Wuhan Jinyintan Hospital Jan 1 to Jan 20, 2020 5–24 99 55⋅5 67 RT-PCR 
(21–82) 
Kaiyuan Sun [30] Multicenter Jan 20- Jan 29, 2020 42 288 49 62.3 CDC guideline 
(2–89) 
Jie Li [31] Dazhou Central Hospital 22 January- February 
10, 2020 
1–21 17 45.1 9 RT-PCR 
(32–65) 
Dawei Wang [15] Zhongnan Hospital of 
Wuhan 
January 1-January 28, 
2020 




Jin Yintan Hospital 
(Wuhan) 
Dec 31, 2019-UN NA 41 49 30 RT-PCR 
(41–58) 
Weijie Guan [17] Multicenter NA NA 1099 47 640 RT-PCR 
(35–58) 
Yang Yang [32] NA NA 51 days 4021 49 2211 NA 
Lei Chen (Chinese) 
[13] 




Multicenter January 18-February 2, 
2020 
12 days 121 45 61 RT-PCR & CT scan 
(18–80) 
Feng Pan [33] Union Hospital 12 Jan-6 Fen 2020 NA 21 40 15 RT-PCR 
(25–63) 
jin Zhang [18] No.7 hospital of Wuhan Jan 16th to Feb 3rd, 
2020 




Tongji hospital in Wuhan January 28-February 
11, 2020 
10 (7–13) 710 63 374 RT-PCR 
(51–71) 
Ming-Yen [34] Hong Kong-Shenzhen 
Hospital 
NA NA 21 56 13 RT-PCR 
(37–65) 
Sijia Tian [35] Beijing Emergency Medical 
Service 
Jan 20 to Feb 10, 2020 Feb.10 20 262 47.5 127 RT-PCR 
(1–94) 
Qun Li [20] NA NA NA 425 15–89 240 WHO guideline 
(26–82) 




13 34 10 NA 
(34–48) 
Xiao-Wei Xu [21] Zhejiang province 10 January   26 
January 2020 




Center for Disease Control, 
Shanghai 
January 20- January 
27, 2020 
NA 51 49 25 CT scan & nucleic 
acid test (16–76) 
Michael Chung 
[37] 
Multicenter January 18–27, 2020 NA 21 51 13 CT scan, NA 
(29–77) 
Zunyou Wu (CDC) 
[38] 
Multicenter through February 11, 
2020 




hospitalized death January 11, 2020 to 
February 10 
30 day 82 72.5 54 rt-pcr  
Bing-Liang Lin [40], Multicenter January 20 to February 19, 29 day 91 50 52 rt-pcr 
Bo Hu [41] Multicenter January 8 to February 9 20 day 50 62 34 rt-pcr 
Chuansheng Zheng [42] Union Hospital, Wuhan 16 Jan 2020 to 15 Feb, 30 day 64 35 23 rtpcr 
Lin Fu [43] Union Hospital January 1 to January 30 30 day 200  99 rtpcr 
Fei Zhou [44] Multicenter   191 56 119 rtpcr 
Guo-Qing Qian [45] Multicenter as of 11 February NA 91 50 37 rt-pcr and clinical 
Guqin Zhang [46] Zhongnan Hospital anuary 2 to February 10, NA 221 55 108 rtpcr 
Qiannan Guo [47] Tongji Hospital UN UN 11 57.55 9 rtpcr 
Hang Fu [48] Chengdu, hospital Jan 1 to Feb 20, NA 52 44.5  rtpcr 
Heshui Shi [49] Union Hospital Dec 20, 2019, and Jan 23 NA 81 49⋅5 42 rtpcr 
Huijun Chen [50] Multicenter 20-Jan NA 9 26–40  rtpcr 
Jian Wu [51] Multicenter 22-Jan NA 80 46.1 39 rtpcr 
Jianlei Cao [52] Multicenter 3-Jan NA 102   rtpcr 
Jie Liu [53] Union Hospital 16 Jan 2020 to 15 Feb NA 64 35 23 rtpcr 
Jing Yuan [54] Shenzhen hospital Jan 23 23rd 2020 to Feb 21 21st NA 25 28 8 rtpcr 
Jinjun Zhang [55] Multicenter Jan 20 to Feb 20, 30 DAY 478 46.9 238 rtpcr 
Jin-Wei Ai [56] Hubei UN UN 102 50.38 52 rtpcr 
Jiong Wu [57] Yancheng City 22-Jan NA 80 44 42 rtpcr 
Jun Chen [58] Shanghai Jan 20 to Feb 6, 14 DAY 249 51 126 rtpcr 
Kaiyuan Sun [59] Multicenter Jan 13 and Jan 31 NA 507 46 281 rtpcr 
Kaiyue Diao [60] Wuhan January 17th to February 5th 30 DAY 6 47.5 3 rtpcr 
Kenneth W. Tsang [61] Hong Kong February 22, 2003, and March 22 30 DAY 10 52.5 5 rtpcr 
Kui Liu [62] Multicenter December 30, 2019 to January 24 24 DAY 137 57 61 rtpcr 
L. Zhang [63] Multicenter Jan 13, 2020, to Feb 26 40 DAY 28 65 17 rtpcr 
Lei Liu [64] Hospital in Chongqing January 20 to February 3, 14 DAY 51 45 32 rtpcr 
lei shu [65] Wuhan Stadium Cabin Hospital Feb 13 to Feb 29, 16 DAY 545 50 264 rtpcr 
Lei Wang [66] Zhengzhou University Jan 21 to Feb 05, 2020, 14 DAY 18 39 10 rtpcr 
Li Yan [67] Tongji Hospital January 10th to February 18th 18 DAY 375 58.83 220 rtpcr 
Li-Li Ren [68] wuhan December 18 to December 29, 2019 12 DAY 5 UN 3 rtpcr 
Lin Fu [69] Union Hospital January 1 to January 30 30 DAY 200 UN 99 rtpcr 
Xiang Li [70] Multicenter 24-Feb-20 NA 292 47⋅83 134 rtpcr 
(continued on next page) 
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gle.com/. Additional search strategy details are provided in Table S1 
(supplementary material) [10]. 
2.2. Study selection 
Duplicate studies were removed using EndNote X7 (Thomson Reu-
ters, New York, NY, USA). Records were initially screened by title and 
abstract by independently two authors (AP, SG). The full-text of 
potentially eligible records was retrieved and examined. Any discrep-
ancies were resolved by consensus. 
2.3. Inclusion criteria 
Studies had to fulfil the following pre-determined criteria to be 
eligible for inclusion in our meta-analysis. Studies were included if they 
reported the number of confirmed cases of patients with demographic 
data, [AND] [OR] clinical data, [AND] [OR] laboratory data, [AND] 
[OR] risk factor data. Confirmed patients were defined as any patient 
with positive nucleic acid testing (most of the studies with Real-Time 
PCR) or those meeting CDC and WHO criteria at the time of their 
publication. 
2.4. Exclusion criteria 
Studies were excluded if they did not report number of confirmed 
cases, were letters to the editor or individual case reports or reviews. 
News reports were also excluded. 
2.5. Data extraction 
All included publications were published in 2020 and all patients are 
from China. The following items were extracted from each article: first 
author, Center and study location in China, sample collection time 
period, patient follow-up time, reference standard for infection confir-
mation, number of confirmed cases, and all demographic, clinical, lab-
oratory data, and risk factor data. Two of our authors (AP and SG) 
independently extracted data and differences were resolved by 
consensus. 
2.6. Quality assessment 
Quality assessments of studies were performed by two reviewers 
independently according to the Critical Appraisal Checklist recom-
mended by the Joanna Briggs Institute [11], and disagreements were 
resolved by consensus. The checklist is composed of nine questions that 
reviewers addressed for each study. The ‘Yes’ answer for each question 
received one point. Thus, final scores for each study could range from 
zero to nine (Table S2 in Supplementary Material). 
2.7. Analysis 
Data cleaning and preparation was done in Microsoft Excel 2010 
(Microsoft©, Redmond, WA, USA) and further analyses were carried out 
via Comprehensive Meta-Analysis Software Version 2.0 (Biostat, Eng-
lewood, NJ). Determination of heterogeneity among the studies was 
undertaken using the chi-squared test (Cochran’s Q) to assess the 
appropriateness of pooling data. We used Random effect model (M   H 
heterogeneity) for pooled results [12]. P values reflect study heteroge-
neity with <0.05 being significant. We also used the Begg’s and Egger’s 
tests based on the symmetry assumption to detect publication bias. 
3. Results 
3.1. Characteristics of included studies 
The process of study selection is displayed in Fig. 1. A total of 36,115 
reports were screened for the analysis of patients with COVID-19, 
36,014 were excluded after title and abstract screening and the full 
text of 342 reports were reviewed in full text. We excluded studies that 
did not report sufficient data and finally 80 studies met the inclusion 
criteria (Fig. 1). Characteristics of the selected articles are summarized 
in Table 1. Of the 80 studies that were included in the analysis, 79 
Table 1 (continued ) 
Bing-Liang Lin [40], Multicenter January 20 to February 19, 29 day 91 50 52 rt-pcr 
Matt Arentz [71] Evergreen hospital February 20, 2020, and March 5 15 DAY 21 70 11 rtpcr 
Naibin Yang [72] Zhejiang 25th January to 28th February NA 10 33 3 rtpcr 
Ping Wu [73] Yichang Central People’s Hospital February 9 to 15 NA 38 65.8 25 rtpcr 
Qifang Bi [74] Shenzhen, January 14 to February 12 25 DAY 391 45 187 rtpcr 
Qiurong Ruan [75] Multicenter   150   rtpcr 
Tao Yao [76] Renmin hospital  NA 55 70.7 37 rtpcr 
Wen Zhao [77] Beijing YouAn Hospital 21st Jan and 8th February 14 DAY 77 52 34 rtpcr 
Yani Kuang [78] Zhejiang January 17, NA 143 47 77 rtpcr 
Yani Kuang [79] Zhejiang, 1-Jan NA 944 47.4 476 rtpcr 
Wan Chen [80] Hospital of Guangxi Zhuang 15-Jan NA 85 41 34 rtpcr 
Xiaomin Luo [81] Renmin hospital Jan 30 to Feb 25 25 DAY 403 56 193 rtpcr 
Xiaoyu Han [82] Union Hospital, December 20 th and February 2 12 DAY 17 40 5 rtpcr 
Xun Li [83] wuhan As of February 13 NA 25 71.48 10 rtpcr 
Yan Deng [84] wuhan January 1, NA 225 54 124 rtpcr 
Yang Wu [85] wuhan 13-Jan NA 14 59 5 ct and rtpcr 
Yangli Liu [86] Guangdong, December 8, 2019, NA 13   rtpcr 
Yanli Liu [87] Hospital of Wuhan January 2 to February NA 109 55 59 rtpcr 
Ying Huang [88] wuhan Jan 21 and Feb 10 20 DAY 36 69.22 25 rtpcr 
Ying Wen [89] Multicenter  NA 417 45.4 197 rtpcr 
Yingjie Wu [90] wuhan 12-Jan NA 402  198 rtpcr 
Yuhui Wang [91] wuhan January 16 to February 17 30 DAY 90 45 33 rtpcr 
Zhibing Lu [92] Multicenter January 1 to February15 15 DAY 123 57.78 61 rtpcr 
Zhiliang Hu [93] Multicenter from Jan 28 to Feb 9, 2020 19 DAY 24   rtpcr 
Ping Yu [94] Shanghai 7-Jan-20 NA 4 74.25  ct scan 
Ali Aminian [95] tehran 9-Feb NA 4 63.5  ct scan 
Hui Yu [96] wuhan Feb. 1 to Mar. 3, NA 105 1–16 year 64 ct scan 
Matthieu Million [97] France, multi center March 3rd to March 31s NA 1061 43.6 
14–95 
492 Ct scan/rt pcr 
Bai shaoli Gansu Prov center 22-january NA 8 53.71 4 Rt pcr 
NA ¼ not known, RT-PCR¼ Real Time Polymerase Chain Reaction, CDC¼ Centers for Disease Control and Prevention, WHO¼World Health Organization, CT scan ¼
CT scan of chest, N ¼ number, IQR ¼ interquartile range. 
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studies were in English and the one of them was in the language of 
Chinese [13]. All studies were retrospective, published in 2020, and all 
patients were from China. 
3.2. Quality assessment 
Quality assessment of included studies were performed based on the 
Critical Appraisal Checklist and the final scores for quality of included 
Table 2 
Demographics, baseline characteristics, and clinical outcomes of patients with confirmed COVID-19.   
Clinical presentation* Confidence interval 95% Heterogeneity test, I2 (%)** Heterogeneity test, P Value** Number of Studies 
Age, years 48 (mean) 43–50 98 <0.001 23 
Sex (Male) 55 (%) 50–57.5 88.4 <0.001 24 
Fever 87 (%) 73–93 98 <0.001 18 
Cough 68 (%) 55.5–74 86 <0.001 18 
Fatigue 39 (%) 29–52.5 93 <0.001 14 
Sputum production/Expectoration 31 (%) 19–39 92 <0.001 9 
Myalgia 24 (%) 14–43 92 <0.001 9 
Dyspnea 24 (%) 12.6–32 92 <0.001 11 
Sore throat 14 (%) 7.8–17 52 0.06 9 
Headache 14 (%) 8.3–18 77 <0.001 16 
Diarrhea 8 (%) 4.6–11.4 70 <0.001 18 
Rhinorrhea 7 (%) 3–12 0 0.43 6 
Nausea and vomiting 6.5 (%) 2.7–13 84 <0.001 6 
Outcome 
Hospitalized 81 (%) 68–94 95 <0.001 7 
Critical condition/ICU 25.6 (%) 6.7–48 99 <0.001 8 
CFR (all age group) 6 (%) 4–8.5 89.6 <0.001 49 
*Age is an exception, presented in mean age in years. ** Greater than 50% is considered high heterogeneity, less than 50% is considered low heterogeneity. A low p 
value (<0.05) is consistent with high heterogeneity. Case fatality rate (CFR). 
Table 3 
Meta-analysis on clinical presentation of case fatality rate (CFR) in different age groups of confirmed COVID-19 cases.  
Age groups (year) CFR (%) Confidence Interval patients Heterogeneity test* 
Lower limit (%) Upper limit (%) Number Studies Included patients I-squared P-value 
All Range 6 4 8.5 49 54,252 89.6 <0.001 
>50 39.5 28.5 52 14 1935 97 <0.001 
<15 0.6 0 0.9 1 82 0 1 
Case fatality rate (CFR), * Greater than 50% is considered high heterogeneity, less than 50% is considered low heterogeneity. A low p value. 
Fig. 2. Forest plot of the meta-analysis on clinical presentation of case fatality rate (CFR) in different age groups of confirmed COVID-19 cases.  
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studies are represented in Table S2 (in supplementary material). In brief, 
studies by Chen [14], Wang [15], Huang [16], Guan [17], Zhang [18], 
Cheng [19], Li [20], Wei Xu [21], and Song [22] had the highest quality 
of the studies available in the purpose of this study. 
3.3. Demographics, baseline characteristics, and clinical characterization 
Table 2 shows that 61, 742 confirmed patients with COVID-19 
infection were included in the Meta-analysis, of which 55% (95% CI 
50–57.5, p < 0.001) were male. The most of the patients had fever 87% 
(95% CI 73–93, p < 0.001) and cough 68% (95% CI 55.5–74, p < 0.001). 
A much smaller proportion of patients had sore throat 14% (95% CI 
7.8–17, p 0.06), headache 14% (95% CI 8.3–18, p < 0.001), diarrhea 8% 
(95% CI 4.6–11.4, p < 0.001), rhinorrhea 7% (95% CI 3–12, p 0.43) or 
nausea and vomiting 6.5% (95% CI 2.7–13, p < 0.001). Most patients 
required hospitalization 81% (95% CI 68–94, p < 0.001), 25.6% (95% CI 
6.7–48, p < 0.001) were deemed to be in critical condition and the 
mortality rate was 6% (95% CI 4–8.5, p < 0.001) between all infected 
patients. Table 3 shows that case fatality rate (CFR) in <15 years old age 
groups was 0.6% (95% CI 0–0.9, p 1), >50 years old was 39.5% (95% CI 
28.5–52, p < 0.001) (Fig. 2), all range group was 6% (95% CI 4–8.5, p <
0.001) (Fig. 3). 
3.4. Clinical characteristics, and Comorbid conditions of patients infected 
with COVID-19 
The majority of patients, 62.5% (95% CI 54.5–79, p < 0.001), had a 
history of recent travel endemic area or contact with them. A significant 
minority of patients (39.5%, 95% CI 20–56, p < 0.001) had a history of 
chronic diseases and 26.5% (95% CI 9.6–49, p < 0.001) had exposure at 
the seafood market(s) (Table 4). 
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper 
rate limit limit Z-Value p-Value Total
Nanshan Chen 0.111 0.063 0.190 -6.502 0.000 11 / 99
Kaiyuan Sun 0.135 0.101 0.180 -10.765 0.000 39 / 288
Chaolin Huang 0.146 0.067 0.290 -3.991 0.000 6 / 41
Weijie Guan 0.014 0.008 0.023 -16.464 0.000 15 / 1099
Lei Chen (Chinese) 0.069 0.017 0.238 -3.552 0.000 2 / 29
Yichun Cheng 0.125 0.103 0.152 -17.140 0.000 89 / 710
Sijia Tian 0.011 0.004 0.035 -7.678 0.000 3 / 262
Zunyou Wu (CDC) 0.023 0.022 0.024 -118.669 0.000 1023 / 44672
Lei Pan 0.176 0.130 0.235 -8.388 0.000 36 / 204
Bicheng Zhang 0.061 0.050 0.076 -23.912 0.000 82 / 1334
Bing-Liang Lin, 0.033 0.011 0.097 -5.755 0.000 3 / 91
Bo Hu 0.320 0.206 0.460 -2.486 0.013 16 / 50
Chengyun Liu 0.072 0.048 0.107 -11.541 0.000 22 / 305
Chuansheng Zheng 0.008 0.000 0.111 -3.423 0.001 0 / 64
De-Xiang Xu 0.170 0.124 0.229 -8.423 0.000 34 / 200
Fei Zhou 0.283 0.223 0.351 -5.794 0.000 54 / 191
Guo-Qing Qian 0.005 0.000 0.081 -3.674 0.000 0 / 91
Guqin Zhang 0.054 0.031 0.093 -9.626 0.000 12 / 221
Qiannan Guo 0.273 0.090 0.586 -1.449 0.147 3 / 11
Hang Fu, 0.009 0.001 0.134 -3.275 0.001 0 / 52
Heshui Shi 0.037 0.012 0.109 -5.538 0.000 3 / 81
Huijun Chen 0.050 0.003 0.475 -2.029 0.042 0 / 9
Jian Wu1 0.006 0.000 0.091 -3.582 0.000 0 / 80
Jianlei Cao 0.167 0.106 0.252 -6.058 0.000 17 / 102
Jie Liu 0.008 0.000 0.111 -3.423 0.001 0 / 64
Jing Yuan 0.019 0.001 0.244 -2.753 0.006 0 / 25
Jinjun Zhang 0.008 0.003 0.022 -9.510 0.000 4 / 478
Jin-Wei Ai 0.029 0.010 0.087 -5.966 0.000 3 / 102
Jun Chen 0.008 0.002 0.032 -6.784 0.000 2 / 249
Kaiyuan Sun1 0.079 0.058 0.106 -14.917 0.000 40 / 507
Kaiyue Diao 0.071 0.004 0.577 -1.748 0.081 0 / 6
Kenneth W. 0.200 0.050 0.541 -1.754 0.080 2 / 10
Kui Liu 0.117 0.073 0.182 -7.606 0.000 16 / 137
Lei Liu 0.020 0.003 0.126 -3.873 0.000 1 / 51
Lei Wang 0.026 0.002 0.310 -2.519 0.012 0 / 18
Li-Li Ren 0.200 0.027 0.691 -1.240 0.215 1 / 5
Lin Fu 0.170 0.124 0.229 -8.423 0.000 34 / 200
Xiang Li 0.140 0.105 0.185 -10.756 0.000 41 / 292
Naibin Yang 0.045 0.003 0.448 -2.103 0.035 0 / 10
Qifang Bi 0.008 0.002 0.024 -8.390 0.000 3 / 391
Qiurong Ruan 0.453 0.376 0.534 -1.141 0.254 68 / 150
Yani Kuang1 0.003 0.000 0.053 -3.995 0.000 0 / 143
Wan Chen 0.012 0.002 0.079 -4.405 0.000 1 / 85
Xiaoyu Han 0.028 0.002 0.322 -2.479 0.013 0 / 17
Yanli Liu 0.284 0.208 0.376 -4.346 0.000 31 / 109
Ying Wen 0.007 0.002 0.022 -8.503 0.000 3 / 417
Yingjie Wu 0.052 0.034 0.079 -12.930 0.000 21 / 402
Yuhui Wang 0.022 0.006 0.085 -5.292 0.000 2 / 90
Bai shaoli 0.125 0.017 0.537 -1.820 0.069 1 / 8
0.058 0.039 0.085 -13.131 0.000 1744 / 54252
-1.00 -0.50 0.00 0.50 1.00
Favours A Favours B
Fig. 3. Forest plot of the meta-analysis on clinical presentation of case fatality rate (CFR) in all age groups of confirmed COVID-19 cases.  
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3.5. Laboratory findings of patients infected with COVID-19 
The laboratory analysis and features showed that the most infected 
patients had increased platelets 61% (95% CI 41–78, p < 0.001), and 
CRP 79% (95% CI 65–91, p < 0.001), while others showed decreased 
lymphocytes, 57.5% (95% CI 42–79, p < 0.001) (Table 5). 
3.6. Chest X-ray and CT scan findings in patients infected with COVID-19 
Analysis showed that the most abnormality which finding with Chest 
X-ray and CT are bilateral involvement of chest radiography 81% (95% 
CI 62.5–87, p < 0.001), consolidation 73.5% (95% CI 50.5–91, p <
0.001), and ground-glass opacity 73.5% (95% CI 40–90, p < 0.001) 
(Table 6). 
4. Discussion 
COVID-19 belongs to the Coronaviridae family and is the newest 
serious zoonotic virus after the related viruses SARS and MERS [23,24]. 
Prior to 2002, coronaviruses were associated with mild respiratory 
illness, but with the emergence of SARS in 2002, MERS in 2012, and now 
in late 2019, COVID-19, establishes that coronaviruses can be associated 
with severe respiratory disease. Genetic variation and phylogenetic 
analysis of these viruses show that the COVID-19 virus has 84% ho-
mology to other beta-coronaviruses, 96% sequence similarity at the 
whole genome level to a bat coronavirus and 79.5% similarity to the 
SARS virus [8,25]. These results suggest that bats are important coro-
navirus reservoirs. 
A study by Adam Bernheim et al. showed that among 121 COVID-19 
patients, fever, cough and sputum production were the most common 
clinical symptoms [3]. Our study found utilizing data from 52,251 pa-
tients with COVID-19 infection, that in additional to these, fatigue and 
myalgia (muscle soreness) were also common. 
The large data set here finds that 81% of patients required hospi-
talization, 25.6% were found to be in critical condition and the mortality 
rate was 6% between all infected patients. The mortality rate is lower 
than some studies (for example, 11% in Nanshan et al. [14]), but still 
higher than many viral infections. It should be recognized that these 
numbers are bias due to the data set including publications related to 
screening practices (e.g. only those with symptoms being screened) 
increased the % value. The true mortality rate from COVID-19 is almost 
certainly much lower than that found in this study. As more data 
emerges from screening asymptomatic or mildly symptomatic in-
dividuals in China and around the world, the true mortality rate will be 
better understood. Additionally, at the time of submission of this 
Table 4 
Clinical Characteristics and Comorbid Conditions of patients with confirmed COVID-19.  




Heterogeneity test, I2 
(%)* 
Heterogeneity test, P 
Value* 
Number of Studies 
reporting 
History of recent travel endemic area or 
contact with them 
62.5 54.5–79 96 <0.001 11 
Chronic diseases 39.5 20–56 95 <0.001 6 
Exposure to seafood market 26.5 9.6–49 95 <0.001 8 
Sick contacts with respiratory illness 18 4.5–39.6 97 <0.001 7 
Hypertension 18 8.5–24.6 97.5 <0.001 17 
ARDS 17.5 4–26.7 95.7 <0.001 8 
Diabetes 9 4–15 96 <0.001 11 
Current smoker 8.2 3.7–15 69 0.01 8 
Chronic liver disease 7 3.8–8.4 6 0.38 12 
Digestive system disease 4.5 2.5–4.9 95 <0.001 8 
Health care worker 16 2–4.6 79 0.008 12 
Past smoker 4 1.1–7.5 80 0.02 6 
Cardiovascular and cerebrovascular diseases 3.3 2.2–2.5 98 <0.001 14 
Chronic respiratory disease 3.2 0.6–8 93 <0.001 7 
Cancer 2.7 0.4–7.4 96.3 <0.001 9 
ARDS ¼ acute respiratory distress syndrome * Greater than 50% is considered high heterogeneity, less than 50% is considered low heterogeneity. A low p value (<0.05) 
is consistent with high heterogeneity. 
Table 5 
















5.3–6.9 3.5–9.5 2961 17 
Increaseda 18.3 
(%) 
6.4–25.6    












0.9–1.06 1.1–3.2 3161 18 
Decreased 57.5 
(%) 






167–205 125–350 2900 15 
Decreased 13 (%) 5–30    
Increased 61 (%) 41–78    
CRPa (mean) 32 
(mg/L) 
19.7–46.5 0–0.5 880 10 














24.5–46 40–55 420 5 






6.8–8.6 0.0–7 509 6 
Increased 56% 42–61 
LDH*** 
(mean) 
286 268–294 120–250 2383 12 
Increased 69.3 
(%) 
58–83    
CRP¼ C Reaction Protein, ESR ¼ Erythrocyte sedimentation rate. WBCs¼White 
blood cells. 
a Increased or Decreased refers to values above or below the normal range. 
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manuscript only ~50% of reported infected patients had recovered (gisa 
nddata.maps.arcgis.com). Lymphopenia, age, multilobular infiltration, 
smoking history, hypertension, and bacterial co-infection have been 
reported as mortality risk factors. Underlying cardiovascular disease 
(40%) and bilateral pneumonia (81%) were common among those who 
have died. Recent travel endemic area or contact with them, exposure to 
persons with respiratory symptoms, and seafood market exposures were 
common amongst those contracting COVID-19. Among 2361 COVID-19 
patients with laboratory data available, leukocytosis was found in 18.3% 
and leukopenia in 28% with lymphocytopenia in 57.5%. Among 2200 
patients, thrombocytosis occurred in 61% and in a smaller sample (n ¼
290) CRP was increased in 79%. 
A study by Yu Zhao et al. showed that ACE2 is a COVID-19 virus 
receptor and that it is normally expressed on pulmonary alveolar 
epithelial cells [26]. ACE2 activates the RAS cascade, which can lead to 
hypertension. The pathology in this pathway can also stimulate fibro-
genesis, inflammation, cell hypertrophy, and cell proliferation [27,28]. 
ACE2 expression is increased in people with pulmonary ARDS and acute 
respiratory injury [29]. The data collected here shows that ARDS 
occurred in 17.5% of reported patients with COVID-19 infection. 
4.1. Limitations 
Several limitations of this study exist. Publication bias and study 
heterogeneity are unavoidable in this type of study, therefore it should 
be considered when interpreting the outcomes of the reports and our 
final data set. Further, this study likely overestimates disease severity 
due to lack of screening of asymptomatic or mildly symptomatic in-
dividuals and subsequent publication bias related to these factors. It is 
very likely that many infected persons have not been detected, thus 
falsely elevating the rates of hospitalization, critical condition, and 
mortality. 
5. Conclusions 
Fever and cough are the most common symptoms of COVID-19 
infection in the literature published to date. Thombocytosis, lympho-
penia, and increased CRP were common lab findings although most 
patients included in the overall analysis did not have laboratory values 
reported. The most common radiographic sign was bilateral involve-
ment in and consolidation. Among Chinese patients with COVID-19, 
rates of hospitalization, critical condition, and hospitalization were 
high in this study, but these findings may be biased by reporting of only 
confirmed cases. 
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